Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Myeloma
100%
Drug Resistance
100%
Drug Resistance Reversal
100%
Multiple Myeloma
100%
Myeloma Cells
87%
Protease Inhibitors
87%
Innate Resistance
75%
Response Mechanism
75%
Resistance Mechanism
75%
Response to Treatment
75%
Acquired Resistance
75%
Patient Tumor
75%
Plasma Cell Neoplasm
75%
Clinical Outcomes
75%
Tumor Subpopulations
75%
Rational Therapeutics
75%
Immunophenotypic Features
75%
Bone Marrow
75%
Combination Therapy
75%
Tumor Response
75%
Therapeutic Development
75%
Germline Variation
75%
Emerging Resistance
75%
Tumor Patients
75%
Tumor Resistance
75%
Refractory Disease
75%
Tumor Cells
75%
Therapeutic Effect
75%
High-throughput Screening
75%
Tumor
75%
Initial Treatment
75%
Drug Response
75%
New Therapies
75%
Inter-individual Variation
75%
Effective Response
75%
Overcoming Resistance
75%
Drug Screening Platform
75%
Glycosylation
25%
Immunomodulatory Drugs (IMiDs)
12%
In Vivo Selection
12%
Mayo Clinic
12%
Unique Resources
12%
University of Minnesota
12%
Bispecific T-cell Engager (BiTE)
12%
Refractor
12%
Patient Samples
12%
CRISPR Off-target
12%
Constantine
12%
Medicine and Dentistry
Drug Resistance
100%
Multiple Myeloma
100%
Neoplasm
75%
Genetics
50%
Myeloma
41%
Myeloma Cell Line
33%
Proteasome Inhibitor
33%
In Vitro
24%
Combination Therapy
24%
Drug Response
24%
Therapy Effect
24%
Germ Cell
24%
Plasmacytoma
24%
High Throughput Screening
24%
Tumor Cell
24%
Diseases
24%
Glycosylation
16%
Immunomodulatory Drug
8%
T Cell
8%
Clustered Regularly Interspaced Short Palindromic Repeat
8%
Immunology and Microbiology
Multiple Myeloma
100%
Drug Resistance
100%
Myeloma Cell Line
45%
Proteasome
45%
Drug Response
37%
Tumor Cell
37%
High Throughput Screening
37%
Germ Cell
37%
Immunoglobulin Producing Cell
37%
In Vitro
37%
Glycosylation
16%
Immunomodulatory Drug
8%
T Cell
8%
Clustered Regularly Interspaced Short Palindromic Repeat
8%